Skip to content

Biologic drug survival in psoriasis, Z.Z.N. Yiu et al.

  • by

Author video for ‘Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)’

My name is dr zenis yu and i’m an nihr academic clinical lecturer in dermatology at the university of manchester i am the lead author on this study investigating the drug survival of adalimumab mustard kinema in patients with psoriasis using data from the british association of dermatologists biologics and immunomodulators register or bad beer why did we do this

Study drug survival or persistence is defined by the duration of time from initiation to discontinuation of therapy and is a proxy marker for effectiveness safety and tolerability of a drug several smaller observational studies have suggested that circuicinoma has a lower drug survival in the real world compared with what is reported in clinical trials we wanted

To investigate the drug survival of psychokinemab and compare this to adalimumab and nostekinumab in patients with psoriasis we also wanted to identify clinical predictors that may have differential effects in the three different biologic cohorts how did we do it we use data from bad bear which is a national registry of patients with psoriasis in the united kingdom

And the republic of ireland that was set up to investigate the long-term safety of biologic therapies we calculated the overall drug survival of the free biologic therapies and calculated drug survival stratified by the reason for discontinuation we then fitted a flexible parametric survival model for drug discontinuation due to ineffectiveness and adjusted

For potential predictors we identified from the literature we tested to see whether these predictors modified the effect between treatment choice and drug discontinuation what were our main findings we had five hundred and forty two patients starting on adeline map 991 starting on secukinumab and three thousand a hundred and eighteen starting on ustekinumab in

Our dataset we found that the overall survival function was similar at 88 percent for both ustekinumab and psychokinemab at one year after initiation with the survival function lower for adelimomab at 78 percent while the predicted drug survival of succukinumab in the model when adjusted for potential confounders was similar to that of ostekinumab and higher

Than that of adelimab we found that the presence of psoriatic arthritis predicted for survival in the adalimumab and psychokinemab cohorts but for discontinuation in the ustekinumab cohort we also found that having had previous exposure to other biologic therapies predicted for discontinuation in the ostekinamab and psychekinemab cohorts but for survival in

The adeline map cohort so why is this study relevant to dermatologists and their patients treated with biologic therapies we found that contrary to previous studies psychokinemab had a high drug survival similar to that of ostekinumab in patients with psoriasis and that both biologics had a higher drug survival compared with adeline map however patients with

Previous exposure to biologic therapies had a markedly lower drug survival with circuit kinemab this is the reason drug survival for psychokinemab was previously reported to be low from the smaller observational studies as they had included predominantly biologic experienced patients we also found that psoriatic arthritis had differential effects in the free

Cohorts these predictors may help patients and clinicians choose the most appropriate biologic therapy based on the individual patients characteristics you

Transcribed from video
Biologic drug survival in psoriasis, Z.Z.N. Yiu et al. By British Journal of Dermatology